Available Technologies

Executive Summary

Patients afflicted with Parkinson’s disease often develop severely debilitating movement disorders as side effects from currently available treatment options. Researchers at MSU propose to use a new gene therapy approach that will both reduce these side effects and prolong the effectiveness of treatment by targeted gene silencing.

Description of Technology

L-Dopa induced dyskinesia (LID) is a side effect of prolonged chronic use of L-Dopa medication. A hyper-expression of Nurr1 protein in affected brain areas might underlie these side effects. Local injection of vectors encoding target genes in affected striatum can directly prevent the hyper-expression allowing for potentially improved fine-tuned response for motor control.

Key Benefits

• Improved quality of life for Parkinson’s patients
• Improved and prolonged benefit for movement disorders

Applications

• Treatment of LID in patients with Parkinson’s disease
• Potentially useful in the treatment of other movement disorders

Click Here to View a Poster on this Technology Presented by the Inventors

Click Here to View a Second Poster on this Technology Presented by the Inventors

Patent Status: 

US patent application published, no. 20170198295; foreign patent application published, no. WO2015188077A1

Licensing Rights Available

Full licensing rights available

Inventors: Fredric Manfredsson, Kathy Steece-Collier, Jack Lipton, Timothy Collier, Nicholas Kanaan, Caryl Sortwell

Tech ID: TEC2014-0099

Alternative contact due to temporary leave:

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.